First Allied Advisory Services’s Whitehawk Therapeutics WHWK Stock Holding History

First Allied Advisory Services’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-800	Closed	-$11K	–	1692
2019 Q2	$11K	Sell	800 -267	-25%	-$4.05K	﹤0.01%	1194
2019 Q1	$15K	Buy	+1,067	New	+$45.9K	﹤0.01%	1150

Other funds holding WHWK

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JIC

Johnson Investment Counsel Cincinnati, Ohio $12.4B AUM 17.21% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

First Allied Advisory Services's WHWK Position: Q3 2019 in Review

First Allied Advisory Services sold out of Whitehawk Therapeutics (WHWK) in Q3 2019, closing a stake of 800 shares — an estimated $11K sold.

First Allied Advisory Services first reported a position in WHWK in Q1 2019 and held it in 2 quarters. The position peaked at $15K in Q1 2019. 24 funds tracked by Wall St. Rank hold WHWK as of Q3 2019.

First Allied Advisory Services reported no remaining Whitehawk Therapeutics position as of Q3 2019 after selling out during the quarter.
First Allied Advisory Services sold 800 Whitehawk Therapeutics shares in Q3 2019, an estimated $11K.
First Allied Advisory Services first reported a position in Whitehawk Therapeutics in Q1 2019 and held it in 2 quarters.
First Allied Advisory Services's Whitehawk Therapeutics position peaked at $15K in Q1 2019.
24 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2019.

Based on First Allied Advisory Services's 13F filing for Q3 2019, filed 6 Nov 2019.